DTIL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than merely 4.06% of US-listed equities with positive expected earnings growth.
Precision Biosciences Inc's stock had its IPO on March 28, 2019, making it an older stock than only 2.55% of US equities in our set.
DTIL's price/sales ratio is 17.45; that's higher than the P/S ratio of 91.27% of US stocks.
Stocks with similar financial metrics, market capitalization, and price volatility to Precision Biosciences Inc are JNCE, MGEN, FULC, SRRK, and RCUS.
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
The FDA designates Precision BioSciences' (DTIL) PBCAR269A, a CAR T cell therapy, for Fast Track review for the treatment of relapsed/refractory multiple myeloma ((MM)).The candidate is currently being evaluated in an open-label, parallel assignment, single-dose, dose-escalation and dose-expansion Phase 1/2a clinical trial in MM patients.Fast Track status provides for more...
Precision BioSciences, Inc. (DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus (HBV) program developed under its 2018 collaboration agreement with Gilead Sciences. “This was a highly productive and well-aligned collaboration, and we deeply value the opportunity to advance our ARCUS genome editing technology and a potential cure for HBV alongside a global leader in infectious disease,” commented Derek Jantz, Ph.D., Chief Scientific Officer, Precision BioSciences.